1. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. (1st October 2019) Authors: Marmorino, F; Rossini, D; Lonardi, S; Moretto, R; Zucchelli, G; Aprile, G; Dell'Aquila, E; Ratti, M; Bergamo, F; Masi, G; Urbano, F; Ronzoni, M; Libertini, M; Borelli, B; Randon, G; Buonadonna, A; Allegrini, G; Pella, N; Ricci, V; Boccaccino, A Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1969 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O-013Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies. (2nd July 2019) Authors: Zucchelli, G; Marmorino, F; Rossini, D; Aprile, G; Casagrande, M; Lonardi, S; Murgioni, S; Dell'Aquila, E; Tomasello, G; Moretto, R; Antoniotti, C; Borelli, B; Urbano, F; Ronzoni, M; Zaniboni, A; Manglaviti, S; Buonadonna, A; Ritorto, G; Masi, G; Allegrini, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-237Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. (20th June 2018) Authors: Dell'Aquila, E; Pantano, F; Rossini, D; Stellato, M; Lonardi, S; Masi, G; Schirripa, M; Marmorino, F; Antoniotti, C; Murgioni, S; Tomasello, G; Ronzoni, M; Racca, P; Vincenzi, B; Allegrini, G; Urbano, F; Buonadonna, A; Banzi, M; Tonini, G; Cremolini, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P-237Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. (20th June 2018) Authors: Dell'Aquila, E; Pantano, F; Rossini, D; Stellato, M; Lonardi, S; Masi, G; Schirripa, M; Marmorino, F; Antoniotti, C; Murgioni, S; Tomasello, G; Ronzoni, M; Racca, P; Vincenzi, B; Allegrini, G; Urbano, F; Buonadonna, A; Banzi, M; Tonini, G; Cremolini, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PD-015Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies. (2nd July 2019) Authors: Rossini, D; Sbrana, A; Bergamo, F; Manai, C; Santini, D; Ghidini, M; Antoniotti, C; Moretto, R; Marmorino, F; Urbano, F; Ronzoni, M; Noventa, S; Randon, G; Carlomagno, C; Latiano, T; Cordio, S; Granetto, C; Cremolini, C; Falcone, A; Antonuzzo, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗